Correlations between HRCT findings and other disease variables in patients with juvenile dermatomyositis (JDM)
| Disease variables (possible range) | HRCT abnormality | HRCT ILD | HRCT calcinosis | HRCT airway |
|---|---|---|---|---|
| Follow-up time | 0.243 | 0.310* | 0.209 | 0.023 |
| TLC, % of predicted | −0.423*** | −0.078 | −0.243 | −0.342* |
| DLCO, % of predicted | −0.085 | 0.025 | −0.065 | −0.025 |
| MDI total (0–40) | 0.346** | 0.266* | 0.376*** | 0.012 |
| HAQ/child-HAQ score (0–3) | 0.392*** | 0.267* | 0.312* | 0.131 |
| SF-36-PCS (0–100) (n=51) | −0.426*** | −0.258 | −0.260 | −0.183 |
| Cumulative prednisolone dose | 0.271* | 0.186 | 0.298* | 0.037 |
Unless otherwise stated n=57; Spearman's correlation coefficients. Presented disease variables were selected based on associations seen in the present study.
↵* p<0.05,
↵** p<0.01;
↵*** p<0.005.
DLCO, diffusing capacity for carbon monoxide; HAQ, Health Assessment Questionnaire; HRCT, high-resolution CT; HRCT airways, bronchiectasis and/or air trapping and/or micronodules; HRCT calcinosis, calcinosis in chest wall (muscle or fascia); HRCT ILD, HRCT-detected interstitial lung disease; MDI, Myositis Damage Index; SF-36-PCS, Short Form-36 Health Survey – physical component summary; TLC, total lung capacity.